Learning from PD-1 Resistance: New Combination Strategies

doi:10.1016/j.molmed.2016.04.008

Trends in Molecular Medicine

Volume 22, Issue 6, June 2016, Pages 448-451

https://doi.org/10.1016/j.molmed.2016.04.008 Get rights and content

Only a minority of cancer patients respond to anti PD-1 immunotherapy. A recent study demonstrates that PD-1 therapy-resistant melanoma patients present distinct signatures of upregulated genes involved in immunosuppression, angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix remodeling, and epithelial–mesenchymal transition (EMT). Combination targeting of these pathways with PD-1 may help overcome PD-1 resistance, thus producing effective antitumor immunity.

Section snippets

Acknowledgments

Research Support: DF/HCC Kidney Cancer SPORE P50CA101942 (G.J.F.). Research supported by Claudia Adams Barr Program for Innovative Cancer Research (K.M.).

References (10)

W. Hugo
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
Cell
(2016)
W. Hugo
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
Cell
(2015)
P.J. Ebert
MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade
Immunity
(2016)
N. Giraldo
Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer
Clin. Cancer Res.
(2015)
S. Koyama
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Nat. Commun.
(2016)

There are more references available in the full text version of this article.

Cited by (54)

Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice
2024, International Immunopharmacology
Melanoma, the most perilous form of skin cancer, is known for its inherent resistance to chemotherapy. Even with advances in tumor immunotherapy, the survival of patients with advanced or recurrent melanomas remains poor. Over time, melanoma tumor cells may produce excessive angiogenic factors, necessitating the use of combinations of angiogenesis inhibitors, including broad-spectrum options, to combat melanoma. Among these inhibitors, Endostatin is one of the most broad-spectrum and least toxic angiogenesis inhibitors. We found Endostatin significantly increased the infiltration of CD8⁺ T cells and reduced the infiltration of M2 tumor-associated macrophages (TAMs) in the melanoma tumor microenvironment (TME). Interestingly, we also observed high expression levels of programmed death 1 (PD-1), an essential immune checkpoint molecule associated with tumor immune evasion, within the melanoma tumor microenvironment despite the use of Endostatin. To address this issue, we investigated the effects of a plasmid expressing Endostatin and PD-1 siRNA, wherein Endostatin was overexpressed while RNA interference (RNAi) targeted PD-1. These therapeutic agents were delivered using attenuated Salmonella in melanoma-bearing mice. Our results demonstrate that pEndostatin-siRNA-PD-1 therapy exhibits optimal therapeutic efficacy against melanoma. We found that pEndostatin-siRNA-PD-1 therapy promotes the infiltration of CD8⁺ T cells and the expression of granzyme B in melanoma tumors. Importantly, combined inhibition of angiogenesis and PD-1 significantly suppresses melanoma tumor progression compared with the inhibition of angiogenesis or PD-1 alone. Based on these findings, our study suggests that combining PD-1 inhibition with angiogenesis inhibitors holds promise as a clinical strategy for the treatment of melanoma.
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
2022, Pharmacology and Therapeutics
Immune checkpoint blockade (ICB) has become well-known in cancer therapy, strengthening the body's antitumor immune response rather than directly targeting cancer cells. Therapies targeting immune inhibitory checkpoints, such as PD-1, PD-L1, and CTLA-4, have resulted in impressive clinical responses across different types of solid tumors. However, as with other types of cancer treatments, ICB-based immunotherapy is hampered by both innate and acquired drug resistance. We previously reported the enrichment of gene signatures associated with wound healing, epithelial-to-mesenchymal, and angiogenesis processes in the tumors of patients with innate resistance to PD-1 checkpoint antibody therapy; we termed these the Innate Anti-PD-1 Resistance Signatures (IPRES). The TGF-β and VEGFA pathways emerge as the dominant drivers of IPRES-associated processes. Here, we review these pathways' functions, their roles in immunosuppression, and the currently available therapies that target them. We also discuss recent developments in the targeting of TGF-β using a specific antibody class termed trap antibody. The application of trap antibodies opens the promise of localized targeting of the TGF-β and VEGFA pathways within the tumor microenvironment. Such specificity may offer an enhanced therapeutic window that enables suppression of the IPRES processes in the tumor microenvironment while sparing the normal homeostatic functions of TGF-β and VEGFA in healthy tissues.
Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer
2021, Biomaterials
Citation Excerpt :
Clinical efficacy of immune checkpoint inhibitors (ICIs) has exhibited unprecedented results in the recent years, however, they have shown to generate no effectual responses against tumors with low active host immunity [1].
Here we report a novel combination of a caspase-cleavable peptide-doxorubicin conjugate (MPD-1) with CD47-antagonizing nanocage therapeutics for the treatment of microsatellite-stable (MSS) colorectal cancer (CRC). MPD-1 (i) upregulated markers of immunogenic cell death (ICD) in tumor, and increased co-stimulatory markers on dendritic cells (DCs), (ii) enhanced CD8⁺ T cell infiltration and antigen presenting cell (APC) activation, and (iii) showed negligible off-target immune-related toxicity compared to free dox. Then, the CD47 antagonist FS nanocage, a SIRPα-expressing ferritin nanocage, was co-administered with MPD-1 that resulted in 95.2% (p < 0.001) tumor growth inhibition in an established CRC model. T cell-mediated elimination of tumors was also confirmed by the tumor-specific activation of T cells detected by IFNγ and tumor-free mice were observed (95%) that bared a memory response when re-challenged. The strategically developed MPD-1 is an ideal adjuvant to immunotherapy and the combination with FS nanocage triggers potent immunity against MSS CRC. In summary, we present an approach to initiate and stimulate immune-mediated eradication of cancer cells using synergistic immunogenic agents targeting the MSS CRC.
Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8<sup>+</sup> T Cell-Derived Interferon-γ
2019, Immunity
Citation Excerpt :
First, our profiling of the tumor-immune microenvironment in the presence of non-suppressive, fragile Treg cells indicates that they maintain their immunosuppressive effects on multiple cell types, particularly M2-like TAMs that in turn increase their tumor occupancy (cell density) and enhance their pro-tumor metabolic function. As suggested by others, the resistance to anti-PD-1 immunotherapy seen in a high proportion of cancer patients is often accompanied by strong immunosuppressive signatures conferred by macrophages, including angiogenesis, extracellular matrix remodeling, and T cell suppressing soluble factors (Bu et al., 2016; Hugo et al., 2016). Our data demonstrate that functional Treg cells promote M2-like TAMs and their pro-tumor gene signature.
Regulatory T (Treg) cells are crucial for immune homeostasis, but they also contribute to tumor immune evasion by promoting a suppressive tumor microenvironment (TME). Mice with Treg cell-restricted Neuropilin-1 deficiency show tumor resistance while maintaining peripheral immune homeostasis, thereby providing a controlled system to interrogate the impact of intratumoral Treg cells on the TME. Using this and other genetic models, we showed that Treg cells shaped the transcriptional landscape across multiple tumor-infiltrating immune cell types. Treg cells suppressed CD8⁺ T cell secretion of interferon-γ (IFNγ), which would otherwise block the activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated fatty acid synthesis in immunosuppressive (M2-like) tumor-associated macrophages (TAMs). Thus, Treg cells indirectly but selectively sustained M2-like TAM metabolic fitness, mitochondrial integrity, and survival. SREBP1 inhibition augmented the efficacy of immune checkpoint blockade, suggesting that targeting Treg cells or their modulation of lipid metabolism in M2-like TAMs could improve cancer immunotherapy.
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
2019, Progress in Molecular Biology and Translational Science
Citation Excerpt :
CAR T-cell therapy has subsequently demonstrated efficacy in patients with advanced diffuse large B-cell NHL and shown promise in patients with CLL, mantle cell lymphoma, multiple myeloma and Hodgkin's lymphoma.7 Despite these successes, ultimately only a minority of cancer patients will respond to immune checkpoint blockade,8 and both oncolytic virotherapy and CAR T-cell therapy remain in a nascent stage of development. Indeed, the latter has thus far proven relatively ineffective in the management of solid tumors.9
For patients with advanced hematological malignancies the therapeutic landscape has been transformed by the emergence of adoptive cell transfer utilizing autologous chimeric antigen receptor (CAR)-redirected T-cells. However, solid tumors have proved far more resistant to this approach. Here, we summarize the numerous challenges faced by CAR T-cells designed to target solid tumors, highlighting, in particular, issues related to impaired trafficking, expansion, and persistence. In parallel, we draw attention to exciting developments in the burgeoning field of oncolytic virotherapy and posit strategies for the synergistic combination of oncolytic viruses with CAR T-cells to improve outcomes for patients with advanced solid tumors.
Targeting T regulatory (T<inf>reg</inf>) cells in immunotherapy-resistant cancers
2024, Cancer Drug Resistance

View all citing articles on Scopus

³: Co-first authors.

View full text

Trends in Molecular Medicine

SpotlightLearning from PD-1 Resistance: New Combination Strategies

Section snippets

Acknowledgments

Cell

Cell

Immunity

Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer

Clin. Cancer Res.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Nat. Commun.

Spotlight
Learning from PD-1 Resistance: New Combination Strategies